The University of Southampton
University of Southampton Institutional Repository
Warning ePrints Soton is experiencing an issue with some file downloads not being available. We are working hard to fix this. Please bear with us.

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease
A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease
Background: the use of cholinesterase inhibitors for Alzheimer's disease (AD) is currently being appraised by the National Institute for Clinical Evidence (NICE). This article provides the latest evidence that NICE will be using as part of this appraisal process.

Objective: to provide a systematic review of the best quality evidence of the effects of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in people with mild to moderately-severe AD.

Design: electronic databases were searched, references of all retrieved articles were checked, and experts were contacted for advice, peer review and to identify additional references. Randomised controlled trials (RCTs) were included if they fulfilled pre-specified criteria. Data were synthesised through a narrative review.

Results: twenty-six RCTs that compared any one of the cholinesterase inhibitors with either a control group or with another cholinesterase inhibitor were included. The quality of reporting and methodology was varied. Treatment with donepezil, rivastigmine or galantamine resulted in significantly better cognitive performance using the ADAS-cog scale when compared with placebo. These findings were generally supported using the MMSE scale. Results from head to head comparisons were limited by the low number of studies and the study quality; generally showing no robust support for any one drug. Few studies evaluated quality of life. Adverse events were generally related to the gastrointestinal system, with a tendency for these to be more common in the treatment arms.

Conclusions: the cholinesterase inhibitors donepezil, rivastigmine, and galantamine can delay cognitive impairment in patients with mild to moderately-severe AD for at least 6 months duration
17-28
Takeda, A.
f6243016-c00a-46eb-bb0d-dbbbc4dcdd6e
Loveman, E.
06ff1bf1-0189-4330-b22d-f5a917e9871d
Clegg, A.
838091f5-39df-4dbe-a369-675b26f2301b
Kirby, J.
5cb348b3-e7cd-44f9-8382-7fa3b93a8580
Picot, J.
324d6f20-a105-49fd-9fb0-88791be84ada
Payne, E.
862f8fcf-711d-4146-a723-a9109339c70a
Green, C.
a4440ea4-08aa-4bde-810e-9b615150e39e
Takeda, A.
f6243016-c00a-46eb-bb0d-dbbbc4dcdd6e
Loveman, E.
06ff1bf1-0189-4330-b22d-f5a917e9871d
Clegg, A.
838091f5-39df-4dbe-a369-675b26f2301b
Kirby, J.
5cb348b3-e7cd-44f9-8382-7fa3b93a8580
Picot, J.
324d6f20-a105-49fd-9fb0-88791be84ada
Payne, E.
862f8fcf-711d-4146-a723-a9109339c70a
Green, C.
a4440ea4-08aa-4bde-810e-9b615150e39e

Takeda, A., Loveman, E., Clegg, A., Kirby, J., Picot, J., Payne, E. and Green, C. (2005) A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. International Journal of Geriatric Psychiatry, 21 (1), 17-28. (doi:10.1002/gps.1402).

Record type: Article

Abstract

Background: the use of cholinesterase inhibitors for Alzheimer's disease (AD) is currently being appraised by the National Institute for Clinical Evidence (NICE). This article provides the latest evidence that NICE will be using as part of this appraisal process.

Objective: to provide a systematic review of the best quality evidence of the effects of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in people with mild to moderately-severe AD.

Design: electronic databases were searched, references of all retrieved articles were checked, and experts were contacted for advice, peer review and to identify additional references. Randomised controlled trials (RCTs) were included if they fulfilled pre-specified criteria. Data were synthesised through a narrative review.

Results: twenty-six RCTs that compared any one of the cholinesterase inhibitors with either a control group or with another cholinesterase inhibitor were included. The quality of reporting and methodology was varied. Treatment with donepezil, rivastigmine or galantamine resulted in significantly better cognitive performance using the ADAS-cog scale when compared with placebo. These findings were generally supported using the MMSE scale. Results from head to head comparisons were limited by the low number of studies and the study quality; generally showing no robust support for any one drug. Few studies evaluated quality of life. Adverse events were generally related to the gastrointestinal system, with a tendency for these to be more common in the treatment arms.

Conclusions: the cholinesterase inhibitors donepezil, rivastigmine, and galantamine can delay cognitive impairment in patients with mild to moderately-severe AD for at least 6 months duration

This record has no associated files available for download.

More information

Published date: 2005

Identifiers

Local EPrints ID: 40610
URI: http://eprints.soton.ac.uk/id/eprint/40610
PURE UUID: 848230a3-4762-48de-a3be-bef41382e22e
ORCID for J. Picot: ORCID iD orcid.org/0000-0001-5987-996X
ORCID for E. Payne: ORCID iD orcid.org/0000-0002-6594-5668

Catalogue record

Date deposited: 07 Jul 2006
Last modified: 09 Jan 2022 03:15

Export record

Altmetrics

Contributors

Author: A. Takeda
Author: E. Loveman
Author: A. Clegg
Author: J. Kirby
Author: J. Picot ORCID iD
Author: E. Payne ORCID iD
Author: C. Green

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×